Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Angelini Labopharm LLC

Latest From Angelini Labopharm LLC

With China CNS Plans, SK Biopharm Completes Strategy For Key Markets

SK Biopharmaceuticals advances into the Greater China market via a CNS focused Chinese company with China’s 6 Dimensions Capital, backed by a large series A financing. It has also licensed its CNS therapy pipeline to the new Chinese operation.

Commercial Deals

Korea Q2 Roundup: Mixed Bag As Pandemic Buoys Some, Hits Others

Two SK Group affiliates benefit from COVID-19 vaccine manufacturing activities and US sales of novel drugs, while other factors such as a recovery in prescription sales, new launches and falling milestone payments affected results at other traditional South Korean pharma firms in the second quarter.

South Korea Companies

Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III

The Phase III clinical trial showed a noticeable placebo effect compared with OV101.

BioPharmaceutical Neurology

Takeda/Ovid Plan Phase III For Soticlestat In Dravet Syndrome, But Pull Back On LGS

A Phase II trial of the CH24H inhibitor showed a statistically significant benefit in children with the rare epilepsy syndrome Dravet Syndrome, but not in Lennox-Gastaut syndrome (LGS).

Neurology Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register